Papillomavirus Infections - 25 Studies Found
Active, not recruiting |
: A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010) : Human Papillomavirus Infection : 2013-11-08 : Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) V503, a 9-va |
Completed |
: Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine : Human Papillomavirus Infection : 2012-09-27 : Other: Prevalence-based model Static prevalence-based model to estimate vaccine effect over a one-year p |
Completed |
: Clinical Evaluation of the APTIMA® HPV 16 18/45 Genotype Assay on the PANTHER® System : Human Papillomavirus Infection : 2012-09-24 : Device: APTIMA HPV Assay In Vitro Diagnostics Assay |
Withdrawn |
: Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri Lanka : Human Papillomavirus Infection : 2012-03-08 :
|
COMPLETED |
: Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066) : Papillomavirus Infections : 2024-11-21 : 9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection |